BACKGROUND: Non-invasive nasopharyngeal carcinoma (NPC) screening usually involves serological testing for the presence of IgA antibodies to Epstein-Barr virus (EBV) capsid antigen (VCA). The present meta-analysis determined the accuracy of VCA-IgA in the diagnosis of NPC. METHODS: A systematic review of studies was conducted and data on the accuracy of VCA-IgA concentrations in the diagnosis of NPC were pooled using random effects models. Receiver operating characteristic curves were used to summarize the overall test performance. RESULTS: Twenty studies met the inclusion criteria for the meta-analysis. The summary estimates for VCA-IgA in the diagnosis of NPC were: sensitivity 0.91 (95% confidence interval (CI): 0.90 - 0.92), specificity 0.92 (95%CI: 0.92 - 0.93), positive likelihood ratio 31.65 (95%CI: 10.99 - 91.15), negative likelihood ratio 0.10 (95%CI: 0.07 - 0.13) and diagnostic odds ratio 414.59 (95%CI: 174.96 - 982.42). The area under the summary receiver operating characteristic curves was 0.98. CONCLUSION: The sensitivity and the specificity of serum VCA-IgA are very high, suggesting that the presence of VCA-IgA in peripheral blood is a valuable predictor for NPC.
BACKGROUND:Non-invasive nasopharyngeal carcinoma (NPC) screening usually involves serological testing for the presence of IgA antibodies to Epstein-Barr virus (EBV) capsid antigen (VCA). The present meta-analysis determined the accuracy of VCA-IgA in the diagnosis of NPC. METHODS: A systematic review of studies was conducted and data on the accuracy of VCA-IgA concentrations in the diagnosis of NPC were pooled using random effects models. Receiver operating characteristic curves were used to summarize the overall test performance. RESULTS: Twenty studies met the inclusion criteria for the meta-analysis. The summary estimates for VCA-IgA in the diagnosis of NPC were: sensitivity 0.91 (95% confidence interval (CI): 0.90 - 0.92), specificity 0.92 (95%CI: 0.92 - 0.93), positive likelihood ratio 31.65 (95%CI: 10.99 - 91.15), negative likelihood ratio 0.10 (95%CI: 0.07 - 0.13) and diagnostic odds ratio 414.59 (95%CI: 174.96 - 982.42). The area under the summary receiver operating characteristic curves was 0.98. CONCLUSION: The sensitivity and the specificity of serum VCA-IgA are very high, suggesting that the presence of VCA-IgA in peripheral blood is a valuable predictor for NPC.
Authors: Shane C McAllister; Duane Shedd; Nancy E Mueller; Ellen T Chang; George Miller; Sumita Bhaduri-McIntosh Journal: J Med Virol Date: 2013-09-30 Impact factor: 2.327
Authors: Matthew G Varga; Hui Cai; Tim Waterboer; Gwen Murphy; Taichi Shimazu; Phil R Taylor; You-Lin Qiao; Sue K Park; Keun-Young Yoo; Sun Ha Jee; Eo Rin Cho; Jeongseon Kim; Christian C Abnet; Shoichiro Tsugane; Qiuyin Cai; Wei Zheng; Michael Pawlita; Xiao-Ou Shu; Meira Epplein Journal: Dig Dis Sci Date: 2018-06-08 Impact factor: 3.199
Authors: M G Cárdenas-Mondragón; J Torres; L Flores-Luna; M Camorlinga-Ponce; R Carreón-Talavera; A Gomez-Delgado; E Kasamatsu; E M Fuentes-Pananá Journal: Br J Cancer Date: 2015-06-09 Impact factor: 7.640
Authors: María G Cárdenas-Mondragón; Ricardo Carreón-Talavera; Margarita Camorlinga-Ponce; Alejandro Gomez-Delgado; Javier Torres; Ezequiel M Fuentes-Pananá Journal: PLoS One Date: 2013-04-24 Impact factor: 3.240
Authors: María G Cárdenas-Mondragón; Javier Torres; Norma Sánchez-Zauco; Alejandro Gómez-Delgado; Margarita Camorlinga-Ponce; Carmen Maldonado-Bernal; Ezequiel M Fuentes-Pananá Journal: J Immunol Res Date: 2017-11-14 Impact factor: 4.818